The retinoic acid paradox in cancer chemoprevention.
Freemantle
Sarah J
SJ
Dragnev
Konstantin H
KH
Dmitrovsky
Ethan
E
D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000517:prevention & control* / Q000556:secondary; D017326:Clinical Trials, Phase III as Topic; D006258:Head and Neck Neoplasms / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage*; D016609:Neoplasms, Second Primary / Q000378:metabolism / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D018168:Receptors, Retinoic Acid / Q000187:drug effects*; D047488:Retinoid X Receptors / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D017211:Treatment Failure
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; C082925:retinoic acid receptor beta; D015474:Isotretinoin